HOWL Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. (HOWL) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.1% since its last earnings release on July 31, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology